Dr. Petrylak on the KEYNOTE-045 Trial for Urothelial Carcinoma

Video

Daniel P. Petrylak, MD, professor of Medicine (Medical Oncology) and Urology, co-director, Signal Transduction Research Program, Yale Cancer Center, 2017 Giant of Cancer Care in Genitourinary Cancer, discusses the KEYNOTE-045 trial investigating pembrolizumab (Keytruda) versus physician’s choice of chemotherapy for patients with urothelial carcinoma.

Daniel P. Petrylak, MD, professor of Medicine (Medical Oncology) and Urology, co-director, Signal Transduction Research Program, Yale Cancer Center, 2017 Giant of Cancer Care in Genitourinary Cancer, discusses the KEYNOTE-045 trial investigating pembrolizumab (Keytruda) versus physician’s choice of chemotherapy for patients with urothelial carcinoma.

KEYNOTE-045 is a randomized trial that compares pembrolizumab to a dealer's choice chemotherapy in patients with urothelial cancer that have been previously treated with platinum-based chemotherapy regimens that could be with carboplatin or cisplatin, explains Petrylak. This trial was the first to demonstrate a survival benefit in favor of the checkpoint inhibitor compared with chemotherapy.

The chemotherapy arm was about 7 months, whereas the checkpoint inhibition arm was about 10 months. That is a significant difference and is clinically meaningful. There is a proportion of patients, about 25%, who do extremely well. They have prolonged durable responses and that is what is really driving the survival benefit in the situation, states Petrylak.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD